FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022331569> ?p ?o ?g. }

• W3022331569 endingPage "2804" @default.
• W3022331569 startingPage "2795" @default.
• W3022331569 abstract "Novel targeted therapies demonstrate improved survival in specific subgroups (defined by genetic variants) of acute myeloid leukemia (AML) patients, validating the paradigm of molecularly targeted therapy. However, identifying correlations between AML molecular attributes and effective therapies is challenging. Recent advances in high-throughput in vitro drug sensitivity screening applied to primary AML blasts were used to uncover such correlations; however, these methods cannot predict the response of leukemic stem cells (LSCs). Our study aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in LSCs. We performed ex vivo sensitivity screening to 46 drugs on 29 primary AML samples at diagnosis or relapse. Using unsupervised hierarchical clustering analysis we identified group with sensitivity to several tyrosine kinase inhibitors (TKIs), including the multi-TKI, dasatinib, and searched for correlations between dasatinib response, exome sequencing and gene expression from our dataset and from the Beat AML dataset. Unsupervised hierarchical clustering analysis of gene expression resulted in clustering of dasatinib responders and non-responders. In vitro response to dasatinib could be predicted based on gene expression (AUC=0.78). Furthermore, mutations in FLT3/ITD and PTPN11 were enriched in the dasatinib sensitive samples as opposed to mutations in TP53 which were enriched in resistant samples. Based on these results, we selected FLT3/ITD AML samples and injected them to NSG-SGM3 mice. Our results demonstrate that in a subgroup of FLT3/ITD AML (4 out of 9) dasatinib significantly inhibits LSC engraftment. In summary we show that dasatinib has an anti-leukemic effect both on bulk blasts and, more importantly, LSCs from a subset of AML patients that can be identified based on mutational and expression profiles. Our data provide a rational basis for clinical trials of dasatinib in a molecularly selected subset of AML patients." @default.
• W3022331569 created "2020-05-13" @default.
• W3022331569 creator A5013463122 @default.
• W3022331569 creator A5013880187 @default.
• W3022331569 creator A5026397928 @default.
• W3022331569 creator A5032269797 @default.
• W3022331569 creator A5034717529 @default.
• W3022331569 creator A5041829729 @default.
• W3022331569 creator A5041902596 @default.
• W3022331569 creator A5046421480 @default.
• W3022331569 creator A5048404435 @default.
• W3022331569 creator A5049823119 @default.
• W3022331569 creator A5080243739 @default.
• W3022331569 creator A5085931737 @default.
• W3022331569 date "2020-05-21" @default.
• W3022331569 modified "2023-10-16" @default.
• W3022331569 title "Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature" @default.
• W3022331569 cites W1988094247 @default.
• W3022331569 cites W1990779222 @default.
• W3022331569 cites W1992601929 @default.
• W3022331569 cites W2005400731 @default.
• W3022331569 cites W2015131391 @default.
• W3022331569 cites W2018326038 @default.
• W3022331569 cites W2021880506 @default.
• W3022331569 cites W2023350410 @default.
• W3022331569 cites W2047406713 @default.
• W3022331569 cites W2051644137 @default.
• W3022331569 cites W2070050178 @default.
• W3022331569 cites W2084855648 @default.
• W3022331569 cites W2093144236 @default.
• W3022331569 cites W2112414163 @default.
• W3022331569 cites W2113752195 @default.
• W3022331569 cites W2115517051 @default.
• W3022331569 cites W2117687396 @default.
• W3022331569 cites W2129615499 @default.
• W3022331569 cites W2132912591 @default.
• W3022331569 cites W2345356016 @default.
• W3022331569 cites W2419140434 @default.
• W3022331569 cites W2579563793 @default.
• W3022331569 cites W2581732250 @default.
• W3022331569 cites W2593230508 @default.
• W3022331569 cites W2623089849 @default.
• W3022331569 cites W2715749014 @default.
• W3022331569 cites W2730666287 @default.
• W3022331569 cites W2767759463 @default.
• W3022331569 cites W2769605488 @default.
• W3022331569 cites W2802234295 @default.
• W3022331569 cites W2896480326 @default.
• W3022331569 cites W2898284215 @default.
• W3022331569 cites W2899472109 @default.
• W3022331569 cites W2904736707 @default.
• W3022331569 cites W2909129451 @default.
• W3022331569 cites W2938588657 @default.
• W3022331569 cites W2961141193 @default.
• W3022331569 cites W2970298208 @default.
• W3022331569 cites W2990749880 @default.
• W3022331569 cites W4236468126 @default.
• W3022331569 cites W4379779275 @default.
• W3022331569 doi "https://doi.org/10.3324/haematol.2019.240705" @default.
• W3022331569 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7726833" @default.
• W3022331569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33256378" @default.
• W3022331569 hasPublicationYear "2020" @default.
• W3022331569 type Work @default.
• W3022331569 sameAs 3022331569 @default.
• W3022331569 citedByCount "12" @default.
• W3022331569 countsByYear W30223315692020 @default.
• W3022331569 countsByYear W30223315692021 @default.
• W3022331569 countsByYear W30223315692022 @default.
• W3022331569 countsByYear W30223315692023 @default.
• W3022331569 crossrefType "journal-article" @default.
• W3022331569 hasAuthorship W3022331569A5013463122 @default.
• W3022331569 hasAuthorship W3022331569A5013880187 @default.
• W3022331569 hasAuthorship W3022331569A5026397928 @default.
• W3022331569 hasAuthorship W3022331569A5032269797 @default.
• W3022331569 hasAuthorship W3022331569A5034717529 @default.
• W3022331569 hasAuthorship W3022331569A5041829729 @default.
• W3022331569 hasAuthorship W3022331569A5041902596 @default.
• W3022331569 hasAuthorship W3022331569A5046421480 @default.
• W3022331569 hasAuthorship W3022331569A5048404435 @default.
• W3022331569 hasAuthorship W3022331569A5049823119 @default.
• W3022331569 hasAuthorship W3022331569A5080243739 @default.
• W3022331569 hasAuthorship W3022331569A5085931737 @default.
• W3022331569 hasBestOaLocation W30223315691 @default.
• W3022331569 hasConcept C121608353 @default.
• W3022331569 hasConcept C126322002 @default.
• W3022331569 hasConcept C143998085 @default.
• W3022331569 hasConcept C194409129 @default.
• W3022331569 hasConcept C2777583451 @default.
• W3022331569 hasConcept C2778461978 @default.
• W3022331569 hasConcept C2778729363 @default.
• W3022331569 hasConcept C2779536868 @default.
• W3022331569 hasConcept C2781187634 @default.
• W3022331569 hasConcept C31734879 @default.
• W3022331569 hasConcept C502942594 @default.
• W3022331569 hasConcept C526805850 @default.
• W3022331569 hasConcept C71924100 @default.
• W3022331569 hasConceptScore W3022331569C121608353 @default.
• W3022331569 hasConceptScore W3022331569C126322002 @default.

• next